Share Price and Basic Stock Data
Last Updated: January 22, 2026, 7:09 am
| PEG Ratio | 0.09 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Ind-Swift Ltd operates in the pharmaceuticals sector, with its shares currently priced at ₹15.8 and a market capitalization of ₹85.4 Cr. Over recent quarters, the company has demonstrated fluctuating sales, with a notable peak of ₹149 Cr in June 2023, followed by a decline to ₹116 Cr in September 2023. The company reported total sales of ₹411 Cr for the year ending March 2023, slightly increasing to ₹515 Cr in March 2025. Despite the growth trajectory, Ind-Swift’s operating profit margin (OPM) stood at -2%, indicating operational challenges. The company’s quarterly performance reflects a pattern of inconsistent profitability, with operating profit reaching ₹18 Cr in December 2022, but dropping to ₹-3 Cr by March 2025. Such revenue trends highlight both potential for recovery and the need for strategic operational improvements to stabilize earnings.
Profitability and Efficiency Metrics
Ind-Swift’s profitability has been volatile, as evidenced by its historical net profit figures. The company recorded a net profit of ₹283 Cr for the fiscal year ending March 2025, a significant recovery from the previous years where it faced losses, including a net loss of ₹364 Cr in March 2017. The return on capital employed (ROCE) stood at 10.53% for March 2025, indicating moderate efficiency in utilizing capital for generating profits. However, the return on equity (ROE) was reported at -70.45%, reflecting considerable challenges in providing returns to shareholders. The cash conversion cycle (CCC) was reported at 120 days, suggesting inefficiencies in managing working capital. The company’s interest coverage ratio (ICR) of 1.80x indicates a precarious position in meeting its interest obligations, which poses a risk to its financial stability.
Balance Sheet Strength and Financial Ratios
Ind-Swift’s balance sheet reveals significant weaknesses, particularly in its reserves, which stood at ₹-413 Cr as of March 2025, indicating a lack of retained earnings to support growth. The company’s borrowings were reported at ₹874 Cr, suggesting reliance on debt financing. The total liabilities amounted to ₹728 Cr, against total assets of ₹728 Cr, indicating a precarious balance between its assets and liabilities. The price-to-book value (P/BV) ratio was recorded at -0.17x, which is considerably below typical sector norms, reflecting negative shareholder equity. The liquidity ratios, with a current ratio of 1.42x and a quick ratio of 1.04x, suggest that the company can cover its short-term obligations, yet the reliance on negative reserves raises concerns about long-term financial health.
Shareholding Pattern and Investor Confidence
The shareholding structure of Ind-Swift Ltd shows that promoters hold a substantial 55.58% stake, which has remained stable over recent quarters, providing some stability in governance. The public holds a 44.42% interest, reflecting a diversified ownership base among retail investors. The number of shareholders increased from 14,422 in September 2022 to 21,588 by March 2025, indicating growing interest and confidence among investors, despite the company’s financial challenges. However, the absence of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) suggests a cautious stance from larger investment entities, which could limit the stock’s upward momentum. This lack of institutional backing may hinder the company’s ability to attract significant capital for expansion or operational improvements.
Outlook, Risks, and Final Insight
The outlook for Ind-Swift Ltd hinges on its ability to navigate operational challenges and improve profitability. The recent net profit of ₹283 Cr is promising but must be sustained to regain investor confidence. Key strengths include a solid revenue base and a stable promoter holding, which can facilitate strategic decisions. However, significant risks include a high debt burden, negative reserves, and poor ROE, all of which could undermine future growth prospects. Should the company successfully implement operational efficiencies and manage its debt, it may present an attractive investment opportunity. Conversely, failure to address these financial weaknesses could lead to further erosion of shareholder value and operational viability.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 130 Cr. | 103 | 203/84.3 | 28.7 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,542 Cr. | 325 | 479/192 | 73.4 | 24.3 | 0.20 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.3 Cr. | 43.5 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 61.1 Cr. | 41.7 | 41.7/17.0 | 145 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,583.58 Cr | 1,090.30 | 47.80 | 202.32 | 0.38% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 106 | 95 | 104 | 107 | 106 | 149 | 116 | 103 | 135 | 114 | 136 | 120 | 145 |
| Expenses | 96 | 90 | 93 | 89 | 98 | 130 | 105 | 98 | 121 | 111 | 122 | 112 | 148 |
| Operating Profit | 10 | 5 | 11 | 18 | 8 | 18 | 11 | 4 | 15 | 3 | 14 | 8 | -3 |
| OPM % | 9% | 5% | 11% | 17% | 8% | 12% | 10% | 4% | 11% | 3% | 11% | 7% | -2% |
| Other Income | 7 | 2 | 1 | 3 | 67 | 6 | 3 | 3 | 46 | 40 | 5 | 2 | 281 |
| Interest | 14 | 15 | 15 | 15 | 14 | 15 | 18 | 15 | 14 | 10 | 10 | 10 | 10 |
| Depreciation | 8 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 5 | 5 | 6 | 7 |
| Profit before tax | -5 | -15 | -11 | -1 | 53 | 2 | -11 | -15 | 40 | 28 | 4 | -6 | 261 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 6% | 0% | 0% | 0% | 2% |
| Net Profit | -5 | -15 | -11 | -1 | 53 | 2 | -11 | -15 | 38 | 28 | 4 | -6 | 257 |
| EPS in Rs | -1.01 | -2.85 | -1.95 | -0.19 | 9.80 | 0.44 | -1.98 | -2.76 | 6.93 | 5.21 | 0.76 | -1.01 | 47.34 |
Last Updated: August 20, 2025, 9:05 am
Below is a detailed analysis of the quarterly data for Ind-Swift Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 145.00 Cr.. The value appears strong and on an upward trend. It has increased from 120.00 Cr. (Dec 2024) to 145.00 Cr., marking an increase of 25.00 Cr..
- For Expenses, as of Mar 2025, the value is 148.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 112.00 Cr. (Dec 2024) to 148.00 Cr., marking an increase of 36.00 Cr..
- For Operating Profit, as of Mar 2025, the value is -3.00 Cr.. The value appears to be declining and may need further review. It has decreased from 8.00 Cr. (Dec 2024) to -3.00 Cr., marking a decrease of 11.00 Cr..
- For OPM %, as of Mar 2025, the value is -2.00%. The value appears to be declining and may need further review. It has decreased from 7.00% (Dec 2024) to -2.00%, marking a decrease of 9.00%.
- For Other Income, as of Mar 2025, the value is 281.00 Cr.. The value appears strong and on an upward trend. It has increased from 2.00 Cr. (Dec 2024) to 281.00 Cr., marking an increase of 279.00 Cr..
- For Interest, as of Mar 2025, the value is 10.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 10.00 Cr..
- For Depreciation, as of Mar 2025, the value is 7.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 6.00 Cr. (Dec 2024) to 7.00 Cr., marking an increase of 1.00 Cr..
- For Profit before tax, as of Mar 2025, the value is 261.00 Cr.. The value appears strong and on an upward trend. It has increased from -6.00 Cr. (Dec 2024) to 261.00 Cr., marking an increase of 267.00 Cr..
- For Tax %, as of Mar 2025, the value is 2.00%. The value appears to be increasing, which may not be favorable. It has increased from 0.00% (Dec 2024) to 2.00%, marking an increase of 2.00%.
- For Net Profit, as of Mar 2025, the value is 257.00 Cr.. The value appears strong and on an upward trend. It has increased from -6.00 Cr. (Dec 2024) to 257.00 Cr., marking an increase of 263.00 Cr..
- For EPS in Rs, as of Mar 2025, the value is 47.34. The value appears strong and on an upward trend. It has increased from -1.01 (Dec 2024) to 47.34, marking an increase of 48.35.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 5:07 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 570 | 417 | 308 | 263 | 270 | 289 | 330 | 356 | 398 | 411 | 502 | 515 |
| Expenses | 602 | 487 | 465 | 328 | 262 | 278 | 306 | 315 | 352 | 369 | 448 | 492 |
| Operating Profit | -32 | -70 | -157 | -65 | 8 | 11 | 23 | 41 | 45 | 42 | 54 | 23 |
| OPM % | -6% | -17% | -51% | -25% | 3% | 4% | 7% | 12% | 11% | 10% | 11% | 4% |
| Other Income | 11 | 2 | 13 | -246 | -20 | 34 | 22 | 14 | 24 | 72 | 53 | 328 |
| Interest | 77 | 40 | 19 | 16 | 7 | 3 | 29 | 52 | 57 | 60 | 63 | 39 |
| Depreciation | 26 | 39 | 36 | 36 | 35 | 34 | 34 | 33 | 32 | 29 | 27 | 24 |
| Profit before tax | -124 | -147 | -200 | -363 | -53 | 8 | -17 | -29 | -20 | 26 | 16 | 288 |
| Tax % | -7% | -2% | 0% | 0% | 1% | 0% | 15% | 1% | 2% | 0% | 14% | 2% |
| Net Profit | -116 | -145 | -200 | -364 | -54 | 8 | -19 | -30 | -20 | 26 | 14 | 283 |
| EPS in Rs | -22.97 | -28.85 | -39.75 | -67.21 | -9.99 | 1.51 | -3.53 | -5.50 | -3.69 | 4.80 | 2.63 | 52.30 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -25.00% | -37.93% | -82.00% | 85.16% | 114.81% | -337.50% | -57.89% | 33.33% | 230.00% | -46.15% | 1921.43% |
| Change in YoY Net Profit Growth (%) | 0.00% | -12.93% | -44.07% | 167.16% | 29.65% | -452.31% | 279.61% | 91.23% | 196.67% | -276.15% | 1967.58% |
Ind-Swift Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | 9% |
| 3 Years: | 9% |
| TTM: | 3% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 18% |
| 3 Years: | 33% |
| TTM: | 132% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 35% |
| 3 Years: | 19% |
| 1 Year: | -33% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Last Updated: September 5, 2025, 7:30 am
Balance Sheet
Last Updated: July 25, 2025, 3:01 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10 | 10 | 10 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 |
| Reserves | 84 | -64 | -264 | -636 | -690 | -688 | -724 | -706 | -731 | -716 | -702 | -413 |
| Borrowings | 1,024 | 1,054 | 1,061 | 1,062 | 1,055 | 1,010 | 1,017 | 1,023 | 1,036 | 993 | 1,014 | 874 |
| Other Liabilities | 272 | 228 | 254 | 232 | 237 | 265 | 298 | 344 | 316 | 361 | 331 | 257 |
| Total Liabilities | 1,390 | 1,228 | 1,061 | 669 | 613 | 598 | 602 | 672 | 632 | 649 | 654 | 728 |
| Fixed Assets | 440 | 404 | 374 | 342 | 311 | 291 | 270 | 244 | 236 | 216 | 184 | 243 |
| CWIP | 4 | 4 | 4 | 2 | 0 | 0 | 0 | 13 | 9 | 30 | 51 | 0 |
| Investments | 45 | 45 | 45 | 44 | 44 | 41 | 24 | 70 | 64 | 54 | 1 | 6 |
| Other Assets | 900 | 775 | 638 | 281 | 258 | 267 | 308 | 344 | 323 | 349 | 418 | 480 |
| Total Assets | 1,390 | 1,228 | 1,061 | 669 | 613 | 598 | 602 | 672 | 632 | 649 | 654 | 728 |
Below is a detailed analysis of the balance sheet data for Ind-Swift Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 11.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 11.00 Cr..
- For Reserves, as of Mar 2025, the value is -413.00 Cr.. The value appears to be improving (becoming less negative). It has improved from -702.00 Cr. (Mar 2024) to -413.00 Cr., marking an improvement of 289.00 Cr..
- For Borrowings, as of Mar 2025, the value is 874.00 Cr.. The value appears to be improving (decreasing). However, Reserves are negative, which is a major warning sign. It has decreased from 1,014.00 Cr. (Mar 2024) to 874.00 Cr., marking a decrease of 140.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 257.00 Cr.. The value appears to be improving (decreasing). It has decreased from 331.00 Cr. (Mar 2024) to 257.00 Cr., marking a decrease of 74.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 728.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 654.00 Cr. (Mar 2024) to 728.00 Cr., marking an increase of 74.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 243.00 Cr.. The value appears strong and on an upward trend. It has increased from 184.00 Cr. (Mar 2024) to 243.00 Cr., marking an increase of 59.00 Cr..
- For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 51.00 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 51.00 Cr..
- For Investments, as of Mar 2025, the value is 6.00 Cr.. The value appears strong and on an upward trend. It has increased from 1.00 Cr. (Mar 2024) to 6.00 Cr., marking an increase of 5.00 Cr..
- For Other Assets, as of Mar 2025, the value is 480.00 Cr.. The value appears strong and on an upward trend. It has increased from 418.00 Cr. (Mar 2024) to 480.00 Cr., marking an increase of 62.00 Cr..
- For Total Assets, as of Mar 2025, the value is 728.00 Cr.. The value appears strong and on an upward trend. It has increased from 654.00 Cr. (Mar 2024) to 728.00 Cr., marking an increase of 74.00 Cr..
However, the Borrowings (874.00 Cr.) are higher than the Reserves (-413.00 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -33.00 | -71.00 | -158.00 | -66.00 | 7.00 | 10.00 | 22.00 | 40.00 | 44.00 | -951.00 | 53.00 | -851.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 282 | 425 | 451 | 151 | 113 | 95 | 104 | 111 | 83 | 93 | 111 | 112 |
| Inventory Days | 202 | 117 | 151 | 86 | 108 | 112 | 102 | 123 | 120 | 150 | 83 | 150 |
| Days Payable | 152 | 155 | 290 | 356 | 426 | 454 | 440 | 454 | 353 | 393 | 262 | 143 |
| Cash Conversion Cycle | 331 | 387 | 311 | -119 | -206 | -246 | -234 | -220 | -149 | -150 | -68 | 120 |
| Working Capital Days | 94 | 2 | -32 | -570 | -563 | -558 | -490 | -482 | -451 | -601 | -30 | 35 |
| ROCE % | -4% | -10% | -20% | -14% | -4% | -4% | 2% | 8% | 11% | 8% | 13% | 12% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 18 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | 52.33 | 2.63 | 4.81 | -3.70 | -9.36 |
| Diluted EPS (Rs.) | 52.33 | 2.63 | 4.81 | -3.70 | -9.36 |
| Cash EPS (Rs.) | 56.67 | 7.63 | 10.10 | 2.23 | -3.60 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | -74.28 | -127.54 | -130.10 | -132.99 | -125.06 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | -74.28 | -127.54 | -130.10 | -132.99 | -125.06 |
| Revenue From Operations / Share (Rs.) | 95.12 | 92.73 | 75.87 | 73.43 | 49.95 |
| PBDIT / Share (Rs.) | 13.03 | 19.66 | 9.95 | 12.72 | 3.04 |
| PBIT / Share (Rs.) | 8.70 | 14.66 | 4.66 | 6.80 | -3.36 |
| PBT / Share (Rs.) | 53.15 | 3.04 | 4.81 | -3.62 | -9.85 |
| Net Profit / Share (Rs.) | 52.33 | 2.63 | 4.81 | -3.70 | -9.99 |
| NP After MI And SOA / Share (Rs.) | 52.33 | 2.63 | 4.81 | -3.70 | -9.31 |
| PBDIT Margin (%) | 13.70 | 21.20 | 13.11 | 17.32 | 6.08 |
| PBIT Margin (%) | 9.14 | 15.80 | 6.13 | 9.25 | -6.71 |
| PBT Margin (%) | 55.87 | 3.27 | 6.33 | -4.92 | -19.72 |
| Net Profit Margin (%) | 55.01 | 2.83 | 6.33 | -5.03 | -20.00 |
| NP After MI And SOA Margin (%) | 55.01 | 2.83 | 6.33 | -5.03 | -18.63 |
| Return on Networth / Equity (%) | -70.45 | -2.06 | -3.69 | 0.00 | 0.00 |
| Return on Capital Employeed (%) | 10.53 | 23.76 | -8.78 | -42.68 | -110.04 |
| Return On Assets (%) | 38.93 | 2.17 | 4.01 | -3.16 | -8.20 |
| Long Term Debt / Equity (X) | -2.07 | -1.44 | -0.55 | -0.85 | -0.98 |
| Total Debt / Equity (X) | -2.17 | -1.45 | -1.39 | -1.44 | -1.54 |
| Asset Turnover Ratio (%) | 0.74 | 0.77 | 0.64 | 0.00 | 0.42 |
| Current Ratio (X) | 1.42 | 1.07 | 0.29 | 0.33 | 0.31 |
| Quick Ratio (X) | 1.04 | 0.86 | 0.19 | 0.24 | 0.23 |
| Inventory Turnover Ratio (X) | 2.62 | 2.69 | 2.45 | 0.00 | 2.97 |
| Interest Coverage Ratio (X) | 1.80 | 1.69 | 0.90 | 1.21 | 2.33 |
| Interest Coverage Ratio (Post Tax) (X) | 1.09 | 1.23 | 0.42 | 0.63 | -2.68 |
| Enterprise Value (Cr.) | 873.08 | 1049.98 | 1018.39 | 1080.08 | 1090.67 |
| EV / Net Operating Revenue (X) | 1.69 | 2.09 | 2.48 | 2.72 | 4.03 |
| EV / EBITDA (X) | 12.37 | 9.86 | 18.90 | 15.68 | 66.27 |
| MarketCap / Net Operating Revenue (X) | 0.13 | 0.19 | 0.09 | 0.15 | 0.14 |
| Price / BV (X) | -0.17 | -0.14 | -0.05 | -0.08 | -0.05 |
| Price / Net Operating Revenue (X) | 0.13 | 0.19 | 0.09 | 0.15 | 0.14 |
| EarningsYield | 4.12 | 0.14 | 0.66 | -0.33 | -1.29 |
After reviewing the key financial ratios for Ind-Swift Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 52.33. This value is within the healthy range. It has increased from 2.63 (Mar 24) to 52.33, marking an increase of 49.70.
- For Diluted EPS (Rs.), as of Mar 25, the value is 52.33. This value is within the healthy range. It has increased from 2.63 (Mar 24) to 52.33, marking an increase of 49.70.
- For Cash EPS (Rs.), as of Mar 25, the value is 56.67. This value is within the healthy range. It has increased from 7.63 (Mar 24) to 56.67, marking an increase of 49.04.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is -74.28. It has increased from -127.54 (Mar 24) to -74.28, marking an increase of 53.26.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is -74.28. It has increased from -127.54 (Mar 24) to -74.28, marking an increase of 53.26.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 95.12. It has increased from 92.73 (Mar 24) to 95.12, marking an increase of 2.39.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 13.03. This value is within the healthy range. It has decreased from 19.66 (Mar 24) to 13.03, marking a decrease of 6.63.
- For PBIT / Share (Rs.), as of Mar 25, the value is 8.70. This value is within the healthy range. It has decreased from 14.66 (Mar 24) to 8.70, marking a decrease of 5.96.
- For PBT / Share (Rs.), as of Mar 25, the value is 53.15. This value is within the healthy range. It has increased from 3.04 (Mar 24) to 53.15, marking an increase of 50.11.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 52.33. This value is within the healthy range. It has increased from 2.63 (Mar 24) to 52.33, marking an increase of 49.70.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 52.33. This value is within the healthy range. It has increased from 2.63 (Mar 24) to 52.33, marking an increase of 49.70.
- For PBDIT Margin (%), as of Mar 25, the value is 13.70. This value is within the healthy range. It has decreased from 21.20 (Mar 24) to 13.70, marking a decrease of 7.50.
- For PBIT Margin (%), as of Mar 25, the value is 9.14. This value is below the healthy minimum of 10. It has decreased from 15.80 (Mar 24) to 9.14, marking a decrease of 6.66.
- For PBT Margin (%), as of Mar 25, the value is 55.87. This value is within the healthy range. It has increased from 3.27 (Mar 24) to 55.87, marking an increase of 52.60.
- For Net Profit Margin (%), as of Mar 25, the value is 55.01. This value exceeds the healthy maximum of 10. It has increased from 2.83 (Mar 24) to 55.01, marking an increase of 52.18.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 55.01. This value exceeds the healthy maximum of 20. It has increased from 2.83 (Mar 24) to 55.01, marking an increase of 52.18.
- For Return on Networth / Equity (%), as of Mar 25, the value is -70.45. This value is below the healthy minimum of 15. It has decreased from -2.06 (Mar 24) to -70.45, marking a decrease of 68.39.
- For Return on Capital Employeed (%), as of Mar 25, the value is 10.53. This value is within the healthy range. It has decreased from 23.76 (Mar 24) to 10.53, marking a decrease of 13.23.
- For Return On Assets (%), as of Mar 25, the value is 38.93. This value is within the healthy range. It has increased from 2.17 (Mar 24) to 38.93, marking an increase of 36.76.
- For Long Term Debt / Equity (X), as of Mar 25, the value is -2.07. This value is below the healthy minimum of 0.2. It has decreased from -1.44 (Mar 24) to -2.07, marking a decrease of 0.63.
- For Total Debt / Equity (X), as of Mar 25, the value is -2.17. This value is within the healthy range. It has decreased from -1.45 (Mar 24) to -2.17, marking a decrease of 0.72.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.74. It has decreased from 0.77 (Mar 24) to 0.74, marking a decrease of 0.03.
- For Current Ratio (X), as of Mar 25, the value is 1.42. This value is below the healthy minimum of 1.5. It has increased from 1.07 (Mar 24) to 1.42, marking an increase of 0.35.
- For Quick Ratio (X), as of Mar 25, the value is 1.04. This value is within the healthy range. It has increased from 0.86 (Mar 24) to 1.04, marking an increase of 0.18.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 2.62. This value is below the healthy minimum of 4. It has decreased from 2.69 (Mar 24) to 2.62, marking a decrease of 0.07.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 1.80. This value is below the healthy minimum of 3. It has increased from 1.69 (Mar 24) to 1.80, marking an increase of 0.11.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.09. This value is below the healthy minimum of 3. It has decreased from 1.23 (Mar 24) to 1.09, marking a decrease of 0.14.
- For Enterprise Value (Cr.), as of Mar 25, the value is 873.08. It has decreased from 1,049.98 (Mar 24) to 873.08, marking a decrease of 176.90.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.69. This value is within the healthy range. It has decreased from 2.09 (Mar 24) to 1.69, marking a decrease of 0.40.
- For EV / EBITDA (X), as of Mar 25, the value is 12.37. This value is within the healthy range. It has increased from 9.86 (Mar 24) to 12.37, marking an increase of 2.51.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.13. This value is below the healthy minimum of 1. It has decreased from 0.19 (Mar 24) to 0.13, marking a decrease of 0.06.
- For Price / BV (X), as of Mar 25, the value is -0.17. This value is below the healthy minimum of 1. It has decreased from -0.14 (Mar 24) to -0.17, marking a decrease of 0.03.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.13. This value is below the healthy minimum of 1. It has decreased from 0.19 (Mar 24) to 0.13, marking a decrease of 0.06.
- For EarningsYield, as of Mar 25, the value is 4.12. This value is below the healthy minimum of 5. It has increased from 0.14 (Mar 24) to 4.12, marking an increase of 3.98.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Ind-Swift Ltd:
- Net Profit Margin: 55.01%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 10.53% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -70.45% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.09
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.04
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 10.9 (Industry average Stock P/E: 47.8)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: -2.17
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 55.01%
Fundamental Analysis of Ind-Swift Ltd
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 781, Industrial Area, Phase II Chandigarh Chandigarh 160002 | corporate@indswift.com http://www.indswiftltd.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. S R Mehta | Executive Chairman |
| Mr. N R Munjal | Non Executive Director |
| Dr. Gopal Munjal | Managing Director & CEO |
| Dr. V R Mehta | Joint Managing Director |
| Mr. Himanshu Jain | Non Executive Director |
| Mr. Rishav Mehta | Non Executive Director |
| Mr. S P Sharma | Independent Director |
| Dr. V K Arora | Independent Director |
| Mr. S C Galhotra | Independent Director |
| Ms. Anoop Michra | Independent Director |
| Mr. Jagvir Singh Ahluwalia | Independent Director |
| Mr. Bhupinder Singh | Independent Director |
Ind-Swift Ltd. Share Price Update | |
|---|---|
| Share Price | Value |
| Today | ₹21.31 |
| Previous Day | ₹20.90 |
FAQ
What is the intrinsic value of Ind-Swift Ltd?
Ind-Swift Ltd's intrinsic value (as of 22 January 2026) is ₹223.60 which is 1315.19% higher the current market price of ₹15.80, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹85.4 Cr. market cap, FY2025-2026 high/low of ₹24.6/12.0, reserves of ₹-413 Cr, and liabilities of ₹728 Cr.
What is the Market Cap of Ind-Swift Ltd?
The Market Cap of Ind-Swift Ltd is 85.4 Cr..
What is the current Stock Price of Ind-Swift Ltd as on 22 January 2026?
The current stock price of Ind-Swift Ltd as on 22 January 2026 is ₹15.8.
What is the High / Low of Ind-Swift Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Ind-Swift Ltd stocks is ₹24.6/12.0.
What is the Stock P/E of Ind-Swift Ltd?
The Stock P/E of Ind-Swift Ltd is 10.9.
What is the Book Value of Ind-Swift Ltd?
The Book Value of Ind-Swift Ltd is 74.2.
What is the Dividend Yield of Ind-Swift Ltd?
The Dividend Yield of Ind-Swift Ltd is 0.00 %.
What is the ROCE of Ind-Swift Ltd?
The ROCE of Ind-Swift Ltd is 11.9 %.
What is the ROE of Ind-Swift Ltd?
The ROE of Ind-Swift Ltd is %.
What is the Face Value of Ind-Swift Ltd?
The Face Value of Ind-Swift Ltd is 2.00.